We’re excited to share a new milestone. Coral Drugs has received the CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia) for Exemestane!

What does this mean?

A CEP is an important certification granted by the European Directorate for the Quality of Medicines (EDQM). It confirms that the API (Active Pharmaceutical Ingredient) meets the strict quality standards of the European Pharmacopoeia, making it easier to supply medicines across Europe and other regulated markets.

Why it matters

Exemestane is a key anti-cancer API, widely used in breast cancer treatment. Adding this to our list of CEP-approved products expands our oncology portfolio and reflects our focus on quality, compliance, and helping patients get access to essential treatments.

Our CEP portfolio at a glance:

‍Respiratory therapies
Budesonide, Ciclesonide, Fluticasone Furoate, Fluticasone Propionate, Triamcinolone Acetonide, Azelastine Hydrochloride, Mometasone Furoate Anhydrous, Formoterol Fumarate Dihydrate, Mometasone Furoate Monohydrate

Anti-inflammatory
Triamcinolone Hexacetonide

Anti-cancer
Flutamide, Exemestane

At Coral, science is at the heart of everything we do and milestones like this take us one step closer to advancing healthcare globally.

#CEPapproval #exemestane #API #EDQM #pharmaceuticalinnovation #globalcompliance #APImanufacturing

You can also learn more about #CoralDrugs through our LinkedIn

‍